InvestorsHub Logo
Followers 18
Posts 3031
Boards Moderated 0
Alias Born 01/28/2017

Re: None

Saturday, 09/14/2019 1:26:28 PM

Saturday, September 14, 2019 1:26:28 PM

Post# of 2165
Fourth quarter will soon be here, load up.

“The Company’s planned Phase 3 registrational randomized, open-label study comparing GPS in the maintenance setting to investigators’ choice of best available treatment in adult AML patients who have achieved hematologic complete remission, with or without thrombocytopenia (CR2/CR2p), after second-line antileukemic therapy and who are deemed ineligible for or unable to undergo allogeneic stem-cell transplantation is expected to be initiated in the fourth quarter of 2019.”
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SLS News